VIA
ALXN

Vantage Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Vantage Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13
Closed -$2K – 820
2016
Q4 		$2K Buy
+13
New +$1.59K ﹤0.01% 731

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vantage Investment Advisors's ALXN Position: Q1 2017 in Review

Vantage Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 13 shares — an estimated $2K sold.

Vantage Investment Advisors first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Vantage Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Vantage Investment Advisors sold 13 Alexion Pharmaceuticals shares in Q1 2017, an estimated $2K.
  • Vantage Investment Advisors first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Vantage Investment Advisors's Alexion Pharmaceuticals position peaked at $2K in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Vantage Investment Advisors's 13F filing for Q1 2017, filed 12 May 2017.